These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37429642)

  • 21. 3-4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles.
    Bese T; Bicer E; Kayan BO; Cebi SS; Acikgoz AS; Turna H; Demirkiran F
    Chemotherapy; 2024; 69(2):122-132. PubMed ID: 38113873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
    Greer A; Gockley A; Manning-Geist B; Melamed A; Sisodia RC; Berkowitz R; Horowitz N; Del Carmen M; Growdon WB; Worley M
    Int J Gynecol Cancer; 2021 Oct; 31(10):1341-1347. PubMed ID: 34429355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study.
    Liu X; Zhao Y; Jiao X; Yu Y; Li R; Zeng S; Chi J; Ma G; Huo Y; Li M; Peng Z; Liu J; Zhou Q; Zou D; Wang L; Li Q; Wang J; Yao S; Chen Y; Ma D; Hu T; Gao Q
    J Ovarian Res; 2023 Jun; 16(1):121. PubMed ID: 37370087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer - retrospective study comparing surgery after 3 cycles or more of chemotherapy.
    Bacry MC; Philippe AC; Riethmuller D; Faucheron JL; Pomel C
    J Gynecol Obstet Hum Reprod; 2022 Sep; 51(7):102409. PubMed ID: 35580803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Thomas QD; Boussere A; Classe JM; Pomel C; Costaz H; Rodrigues M; Ray-Coquard I; Gladieff L; Rouzier R; Rouge TM; Gouy S; Barranger E; Sabatier R; Floquet A; Marchal F; Guillemet C; Polivka V; Martin AL; Colombo PE; Fiteni F
    Gynecol Oncol; 2022 Oct; 167(1):11-21. PubMed ID: 35970603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
    Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H
    J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
    Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
    Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival.
    Coada CA; Dondi G; Ravegnini G; Di Costanzo S; Tesei M; Fiuzzi E; Di Stanislao M; Giunchi S; Zamagni C; Bovicelli A; Hrelia P; Angelini S; De Iaco P; Perrone AM
    J Gynecol Oncol; 2023 Nov; 34(6):e82. PubMed ID: 37743060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
    Bogani G; Matteucci L; Tamberi S; Arcangeli V; Ditto A; Maltese G; Signorelli M; Martinelli F; Chiappa V; Leone Roberti Maggiore U; Perotto S; Scaffa C; Comerci G; Stefanetti M; Raspagliesi F; Lorusso D
    Int J Gynecol Cancer; 2017 Nov; 27(9):1856-1862. PubMed ID: 29064913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer.
    Minareci Y; Sozen H; Ak N; Tosun OA; Saip P; Salihoglu MY; Topuz S
    Chemotherapy; 2022; 67(1):1-11. PubMed ID: 34784598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.
    Nagao S; Tamura J; Shibutani T; Miwa M; Kato T; Shikama A; Takei Y; Kamiya N; Inoue N; Nakamura K; Inoue A; Yamamoto K; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2023 Jun; 28(6):804-815. PubMed ID: 37140771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
    Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
    Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Davidson BA; Broadwater G; Crim A; Boccacio R; Bixel K; Backes F; Previs RA; Salinaro J; Salani R; Moore K; Secord AA
    Gynecol Oncol; 2019 Mar; 152(3):554-559. PubMed ID: 30558972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.